CTOs on the Move

Resilience Technology Corporation

www.resilience.com

 
Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Robert Brown
Senior Director of Cyber Resilience Profile
Michael Good
Director Security Operations Profile
Brandy Duso
Director of Compliance and Risk Profile
Bill Reid
CISO and VP, Security and Privacy Profile
Chris Taylor
Senior Director Information Technology Profile

Funding

Resilience Technology Corporation raised $750M on 11/23/2020
Resilience Technology Corporation raised $625M on 06/06/2022

Similar Companies

Alios BioPharma

Alios BioPharma is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Linden Labs

Linden Labs is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abpro

We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.

Immuneering

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering`s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

Bionest Partners

Bionest Partners is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.